DiaMedica Therapeutics (DMAC) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed YD Bio (YDES) over the past year, gaining 15.0% versus a loss of 70.5%. YD Bio is the larger company by market cap ($419.3 million vs $408.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | YDES |
|---|---|---|
| Share price | $7.57 | $5.92 |
| Market cap | $408.22M | $419.32M |
| 1-day change | -5.85% | -12.17% |
| YTD return | -4.90% | -51.44% |
| 1-year return | +15.05% | -70.53% |
| 5-year return | +88.31% | — |
| EPS (TTM) | $-0.72 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $596.82K |
| Revenue growth (YoY) | — | +16.94% |
| Net income (latest FY) | $-32.77M | $-8.31M |
| Gross margin | — | 28.05% |
| Operating margin | — | -883.31% |
| Net margin | — | -1392.61% |
| 52-week high | $10.42 | $22.00 |
| 52-week low | $5.25 | $1.70 |
| Distance from 52-week high | -27.35% | -73.09% |
| Analyst consensus | none | — |
| Avg. price target upside | +104.76% | — |
| Average volume | 182.81K | 289.85K |
| Shares outstanding | 53.93M | 70.83M |
| Employees | 35 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed YDES by 85.6 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Healthcare · Biotechnology · 13 employees
DMAC vs YDES FAQ
Which is bigger, DiaMedica Therapeutics or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $419.32M compared with $408.22M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or YDES?
DMAC returned +15.05% over the past 12 months, compared with -70.53% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and YD Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.